Ulrik Nielsen
Founder at MERRIMACK PHARMACEUTICALS, INC.
Net worth: 546 017 $ as of 2024-03-30
Profile
Ulrik B.
Nielsen is the founder of Merrimack Pharmaceuticals, Inc. (founded in 1993) where he holds the title of Independent Director.
He was also the founder of Torque Therapeutics, Inc. (founded in 2015) where he held the title of Chairman & President from 2017 to 2018.
Dr. Nielsen's current job(s) include being the President, CEO, Treasurer & Director at Tidal Therapeutics, Inc. since 2018 and a Director at Alloy Therapeutics LLC since 2019.
Dr. Nielsen's former job(s) include being the Chief Executive Officer at Silver Creek Pharmaceuticals, Inc. from 2010 to 2014 and serving as the Executive Chairman-Management Board at Notch Therapeutics, Inc.Dr. Nielsen obtained his graduate and doctorate degrees from the University of Copenhagen.
Known holdings in public companies
Company | Date | Number of shares | Valuation | Valuation date |
---|---|---|---|---|
2024-03-14 | 36,968 ( 0.25% ) | 546 017 $ | 2024-03-30 |
Ulrik Nielsen active positions
Companies | Position | Start |
---|---|---|
MERRIMACK PHARMACEUTICALS, INC. | Founder | 1992-12-31 |
Tidal Therapeutics, Inc.
Tidal Therapeutics, Inc. Miscellaneous Commercial ServicesCommercial Services Part of Sanofi, Tidal Therapeutics, Inc. is a preclinical biotech company based in Quincy, MA. Tidal Therapeutics, Inc. focuses on developing nanoparticles that deliver to reprogram immune cells inside the body, with applications in oncology and immune diseases. Ulrik B. Nielsen has been the CEO of the company since 2018. Tidal Therapeutics was acquired by Sanofi on April 09, 2021 for $470 million. | Chief Executive Officer | 2018-07-31 |
Alloy Therapeutics LLC
Alloy Therapeutics LLC Miscellaneous Commercial ServicesCommercial Services Alloy Therapeutics LLC is a biotechnology ecosystem company that democratizes access to tools, technologies, services, and company creation capabilities for discovering and developing therapeutic biologics. The company's lead offering is the ATX-GX™ platform, a human therapeutic antibody discovery platform consisting of a growing suite of proprietary transgenic mice strains. Through a community of partners across academia, biotech, and the largest biopharma, Alloy is a leader in bispecific antibody discovery and engineering services, utilizing its proprietary ATX-CLC common light chain platform integrating novel transgenic mice and phage display. Founded in 2017 and privately funded by visionary investors, Alloy is headquartered in Hanover, NH, with European labs in Switzerland. The company was founded by Errik B. Anderson, who has been the CEO since incorporation. | Director/Board Member | 2018-12-31 |
Former positions of Ulrik Nielsen
Companies | Position | End |
---|---|---|
Torque Therapeutics, Inc.
Torque Therapeutics, Inc. BiotechnologyHealth Technology Torque Therapeutics, Inc. develops immunotherapies to address cancers focused on the specific modulation of immune cell subsets. The company was founded by Bart Henderson, Ulrik B. Nielsen, Darrell J. Irvine, and Thomas Lars Andresen and is headquartered in Cambridge, MA. | Chief Executive Officer | 2017-11-13 |
Silver Creek Pharmaceuticals, Inc.
Silver Creek Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology Silver Creek Pharmaceuticals, Inc. develops novel regenerative medicines. The firm focuses on treating cardiovascular disease. Its molecules are designed to promote resilience and regeneration of damaged tissues after acute or chronic injury. The company was founded in 2010 and is headquartered in San Francisco, CA. | Chief Executive Officer | 2014-02-28 |
Notch Therapeutics, Inc.
Notch Therapeutics, Inc. Pharmaceuticals: OtherHealth Technology Notch Therapeutics, Inc. engages in the development of cell therapies for the treatment of diseases. It offers technology platform, which uses genetically tailored stem cells as a renewable source for creating allogeneic T cell therapies that expand treatment options and deliver cell immunotherapies to patients. The company was founded by Juan Carlos Zuniga-Pflucker and Peter Zandstra in 2018 and is headquartered in Toronto, Canada. | Chief Executive Officer | 2020-07-19 |
Training of Ulrik Nielsen
University of Copenhagen | Doctorate Degree |
Experiences
Positions held
Connections
1st degree connections
1st degree companies
Male
Female
Members of the board
Executives
Linked companies
Listed companies | 1 |
---|---|
MERRIMACK PHARMACEUTICALS, INC. | Health Technology |
Private companies | 5 |
---|---|
Silver Creek Pharmaceuticals, Inc.
Silver Creek Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology Silver Creek Pharmaceuticals, Inc. develops novel regenerative medicines. The firm focuses on treating cardiovascular disease. Its molecules are designed to promote resilience and regeneration of damaged tissues after acute or chronic injury. The company was founded in 2010 and is headquartered in San Francisco, CA. | Health Technology |
Torque Therapeutics, Inc.
Torque Therapeutics, Inc. BiotechnologyHealth Technology Torque Therapeutics, Inc. develops immunotherapies to address cancers focused on the specific modulation of immune cell subsets. The company was founded by Bart Henderson, Ulrik B. Nielsen, Darrell J. Irvine, and Thomas Lars Andresen and is headquartered in Cambridge, MA. | Health Technology |
Notch Therapeutics, Inc.
Notch Therapeutics, Inc. Pharmaceuticals: OtherHealth Technology Notch Therapeutics, Inc. engages in the development of cell therapies for the treatment of diseases. It offers technology platform, which uses genetically tailored stem cells as a renewable source for creating allogeneic T cell therapies that expand treatment options and deliver cell immunotherapies to patients. The company was founded by Juan Carlos Zuniga-Pflucker and Peter Zandstra in 2018 and is headquartered in Toronto, Canada. | Health Technology |
Tidal Therapeutics, Inc.
Tidal Therapeutics, Inc. Miscellaneous Commercial ServicesCommercial Services Part of Sanofi, Tidal Therapeutics, Inc. is a preclinical biotech company based in Quincy, MA. Tidal Therapeutics, Inc. focuses on developing nanoparticles that deliver to reprogram immune cells inside the body, with applications in oncology and immune diseases. Ulrik B. Nielsen has been the CEO of the company since 2018. Tidal Therapeutics was acquired by Sanofi on April 09, 2021 for $470 million. | Commercial Services |
Alloy Therapeutics LLC
Alloy Therapeutics LLC Miscellaneous Commercial ServicesCommercial Services Alloy Therapeutics LLC is a biotechnology ecosystem company that democratizes access to tools, technologies, services, and company creation capabilities for discovering and developing therapeutic biologics. The company's lead offering is the ATX-GX™ platform, a human therapeutic antibody discovery platform consisting of a growing suite of proprietary transgenic mice strains. Through a community of partners across academia, biotech, and the largest biopharma, Alloy is a leader in bispecific antibody discovery and engineering services, utilizing its proprietary ATX-CLC common light chain platform integrating novel transgenic mice and phage display. Founded in 2017 and privately funded by visionary investors, Alloy is headquartered in Hanover, NH, with European labs in Switzerland. The company was founded by Errik B. Anderson, who has been the CEO since incorporation. | Commercial Services |
- Stock Market
- Insiders
- Ulrik Nielsen